XML 43 R30.htm IDEA: XBRL DOCUMENT v3.25.3
Segment Reporting - Schedule of Significant Expenses (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2025
Jun. 30, 2025
Mar. 31, 2025
Sep. 30, 2024
Jun. 30, 2024
Mar. 31, 2024
Sep. 30, 2025
Sep. 30, 2024
Revenues from External Customers and Long-Lived Assets [Line Items]                
Oncology clinical trial related costs $ 131,096     $ 37,724     $ 390,382 $ 99,395
Acquired in-process research and development expense 0     0     0 15,007
Stock-based compensation 130,761     19,371     620,641 39,966
Total operating expenses 234,211     58,378     869,499 160,384
Other income, net 2,418     4,578     9,085 8,949
Interest expense 0     (2,454)     0 (8,677)
Net loss (231,793) $ (565,708) $ (62,913) (56,254) $ (60,385) $ (43,473) (860,414) (160,112)
Reportable Segment                
Revenues from External Customers and Long-Lived Assets [Line Items]                
Oncology clinical trial related costs 75,236     22,980     179,423 64,832
Acquired in-process research and development expense 0     0     0 15,007
Compensation related costs, excluding stock-based compensation 21,469     12,840     54,123 32,751
Stock-based compensation 130,761     19,371     620,641 39,966
Other expenses 6,745     3,187     15,312 7,828
Total operating expenses 234,211     58,378     869,499 160,384
Other income, net 2,418     4,578     9,085 8,949
Interest expense 0     (2,454)     0 (8,677)
Net loss $ (231,793)     $ (56,254)     $ (860,414) $ (160,112)